Exercising 2.5 Hours Per Week Associated with Slower Declines in Parkinson’s Disease Patients

According to a new report published in the Journal of Parkinson’s Disease

March 24, 2017 - Amsterdam, NL – Parkinson’s disease (PD) is a progressive condition that often results in mobility impairments and can lead to decreased health-related quality of life (HRQL) and death. There is evidence that physical activity can delay decline in PD patients. In a study in the Journal of Parkinson’s Disease, researchers determined that that people who exercised regularly had significantly slower declines in HRQL and mobility over a two-year period. More...

March 24, 2017

Journal of Parkinson’s Disease Celebrates Key Breakthroughs that Shaped PD Research over the Last 200 Years

From the shaking palsy to alpha-synuclein, the stories behind the science from many of the researchers who played key roles in achieving significant milestones are published

March 22, 2017 - Amsterdam, The Netherlands - Marking the 200th anniversary of James Parkinson’s first published description of the disease that would come to bear his name, the Journal of Parkinson’s Disease is proud to publish Milestones in 200 Years of Parkinson’s Disease Research. This special issue features commentaries by luminaries in the field, who are responsible for some of the greatest advances in understanding and treating the disease since it was first characterized. The issue is openly available as a service to the Parkinson’s disease (PD) community. More...

March 22, 2017

Insulin Resistance May Lead to Faster Cognitive Decline

Executive function and memory are particularly vulnerable to the effects of insulin resistance, Tel Aviv University researchers say

March 21, 2017 - Tel Aviv – A new Tel Aviv University study published in the Journal of Alzheimer's Disease finds that insulin resistance, caused in part by obesity and physical inactivity, is also linked to a more rapid decline in cognitive performance. According to the research, both diabetic and non-diabetic subjects with insulin resistance experienced accelerated cognitive decline in executive function and memory. More...

March 21, 2017

Alzheimer’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some

March 17, 2017 -

A new study published in the Journal of Alzheimer's Disease shows Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.

More...

March 17, 2017